SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for its motion sickness drug, NEREUS, marking the first new treatment in this category in decades. The community is actively discussing the significant upside potential, fueled by this approval and upcoming PDUFA dates for other pipeline candidates, with many highlighting its potential off-label use for GLP-1 induced nausea. Traders are debating whether to hold for long-term growth driven by a diversified portfolio or capitalize on immediate short-term volatility.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as a vibrant hub for new meme coin projects and communities, with symbols like $RAGE and $COCK actively discussed. The community remains focused on long-term staking and holding, viewing $SOL as a high-performance blockchain with a rapidly expanding ecosystem for DeFi and NFTs, despite recent market fluctuations.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is a top trending meme coin, fueled by an exceptionally active community passionately advocating its status as an "OG meme" originating from Rage Comics. This dedicated base is consistently building out an ecosystem with projects like RageMaker and RageGames, expressing strong conviction for substantial long-term growth and widespread recognition in the crypto space. They are frequently seen battling other meme coins for trending dominance and market attention.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is actively trending, with investors sharply divided between frustration over persistent price declines and high short interest, and conviction in its long-term growth story. The community is buzzing with speculation about potential partnerships following recent oral GLP-1 pill approvals, viewing current levels as a significant accumulation opportunity despite ongoing market pressures. Many anticipate a strong rebound fueled by expanding services and international reach, alongside the potential for a short squeeze.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics (CORT) is trending as its PDUFA deadline for the Relacorilant drug for Cushing's syndrome drives intense speculation among investors. The community is sharply divided between expecting approval and fearing a Complete Response Letter, fueled by unusual trading volumes, the absence of a trading halt, and active discussions around potential short-seller influence.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is trending amidst growing investor frustration as the stock continues to mark new lows, fueling intense debate around its management team and the prolonged absence of a permanent CEO. The community is actively discussing the disconnect between the acclaimed vehicle technology and the company's market performance, with many questioning impending production targets and speculating on potential short squeezes or further strategic shifts.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is trending amidst intense debate, primarily driven by ongoing selling pressure from early SPAC investors and end-of-year tax loss harvesting. Community sentiment is sharply divided, with optimistic investors highlighting the company's profitability and long-term growth potential as a buying opportunity, while skeptics point to continuous dilution and recent price declines, fueling concerns about its trajectory and comparing it to other volatile Chinese-linked equities.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is generating significant buzz as investors eagerly anticipate potential announcements at the upcoming CES 2026, supported by recent analyst upgrades and reports of institutional buying. Bulls are accumulating shares, confident in the company's strong revenue growth, substantial backlog, and debt-free balance sheet amidst a perceived oversold condition and year-end tax loss selling. Conversely, a skeptical contingent highlights sustained price declines and insider selling, questioning management's transparency and the long-term stability of this agentic AI voice technology leader.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with sharply divided community sentiment, as many express frustration over its current price performance and question its long-term utility. Despite this, a significant segment of holders remains optimistic, anticipating a future rally driven by potential integrations and a broader market rebound. The debate continues between its meme-driven appeal and the demand for more foundational crypto infrastructure.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is trending after announcing a proposed business combination with Applied Digital Corporation to spin out an AI-focused cloud computing platform, ChronoScale. This potential pivot into AI infrastructure, combined with the stock's low float, has fueled a strong speculative rally and short squeeze sentiment. The community is actively discussing massive upside potential and high trading volume, though some voice concerns about potential shareholder dilution from the deal.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Consensus Rating of "Hold" from Brokerages

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) has earned a consensus recommendation of "Hold" from the eight research firms that are presently covering the company, MarketBeat.com...

129,339 Shares in Amphastar Pharmaceuticals, Inc. $AMPH Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) during the 3rd quarter, according to the company in its most recent disclosure...

Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?

CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.

Squarepoint Ops LLC Lowers Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH

Squarepoint Ops LLC cut its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 67.0% during the second quarter, according to the company in its most recent...

Insider Selling: Amphastar Pharmaceuticals (NASDAQ:AMPH) EVP Sells 9,787 Shares of Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The...

CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock?

CorMedix surges on strong DefenCath uptake as sales climb while the Melinta acquisition expands and diversifies its commercial portfolio.

Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to "Hold" at Barclays

Barclays upgraded Amphastar Pharmaceuticals to a "hold" rating in a research report on Monday...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Coverage Initiated by Analysts at Barclays

Barclays initiated coverage on Amphastar Pharmaceuticals in a research note on Tuesday. They set an "equal weight" rating and a $30.00 target price for the company...

Marshall Wace LLP Sells 183,037 Shares of Amphastar Pharmaceuticals, Inc. $AMPH

Marshall Wace LLP decreased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 17.7% in the 2nd quarter, according to the company in its most recent filing with the...

Amphastar Pharmaceuticals, Inc. $AMPH Shares Bought by Quantbot Technologies LP

Quantbot Technologies LP increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 188.8% during the second quarter, according to the company in its most recent 13F...

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	$0.93	--	--	N/A
Q3 '25	$0.83	$0.93	12.68%	BEAT
Q2 '25	$0.74	$0.85	14.61%	BEAT
Q1 '25	$0.69	$0.74	7.77%	BEAT
Q4 '24	$0.94	$0.92	-1.95%	MISSED

AMPH
Amphastar Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AMPH News

AMPHAmphastar Pharmaceuticals Inc